Charles Schwab
SER icon

Charles Schwab’s Serina Therapeutics SER Stock Holding History

Charles Schwab’s Portfolio SER Stock Details SER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-303
Closed -$17K – 3524
2020
Q4 		$17K Hold
303
– – ﹤0.01% 3377
2020
Q3 		$9K Hold
303
– – ﹤0.01% 3336
2020
Q2 		$11K Sell
303
-1,257
-81% -$37K ﹤0.01% 3312
2020
Q1 		$52K Hold
1,560
– – ﹤0.01% 3154
2019
Q4 		$100K Hold
1,560
– – ﹤0.01% 3097
2019
Q3 		$108K Hold
1,560
– – ﹤0.01% 3092
2019
Q2 		$202K Buy
1,560
+705
+82% +$95.4K ﹤0.01% 3087
2019
Q1 		$122K Buy
855
+303
+55% +$44.3K ﹤0.01% 3080
2018
Q4 		$59K Buy
+552
New +$70.2K ﹤0.01% 3125

Other funds holding SER

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Charles Schwab's SER Position: Q1 2021 in Review

Charles Schwab sold out of Serina Therapeutics (SER) in Q1 2021, closing a stake of 303 shares — an estimated $17K sold.

Charles Schwab first reported a position in SER in Q4 2018 and held it in 9 quarters. The position peaked at $202K in Q2 2019. 36 funds tracked by Wall St. Rank hold SER as of Q1 2021.

  • Charles Schwab reported no remaining Serina Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Charles Schwab sold 303 Serina Therapeutics shares in Q1 2021, an estimated $17K.
  • Charles Schwab first reported a position in Serina Therapeutics in Q4 2018 and held it in 9 quarters.
  • Charles Schwab's Serina Therapeutics position peaked at $202K in Q2 2019.
  • 36 funds tracked by Wall St. Rank held Serina Therapeutics as of Q1 2021.

Based on Charles Schwab's 13F filing for Q1 2021, filed 17 May 2021.